

SCHEDULING STATUS:

S4

PROPRIETARY NAME AND DOSAGE FORM:

LARACIT 100 mg (injection)

LARACIT 500 mg (injection)

PHARMACOLOGICAL CLASSIFICATION:

A26 Cytostatics

COMPOSITION:

Each vial contains 100 mg per 2 ml solution.

Each 5 ml vial of **LARACIT 100 mg** contains 100 mg cytarabine.

Each 14 ml vial of **LARACIT 500 mg** contains 500 mg cytarabine.

PHARMACOLOGICAL ACTION:

Cytarabine is an antimetabolite of the series of pyrimidine antagonists and inhibits the formation of desoxycytidine triphosphate, and thus DNA synthesis, by blocking the reduction of cytidine phosphate to desoxycytidine phosphate.

INDICATIONS:

LARACIT 100 mg is indicated in the treatment of adults and children with:

Acute non-lymphocytic leukaemia

Acute lymphocytic leukaemia. Blast crisis in chronic myeloid leukaemia (CML).

In combination with other agents, for the treatment of Non- Hodgkin Lymphomas of high malignancy in adults and children.

LARACIT 500 mg is indicated in the treatment of adults and children with:

Refractory acute non-lymphocytic leukaemias Refractory acute lymphocytic leukaemias
Blast crisis of chronic myeloid leukaemia (CML) High risk leukaemias such as
acute leukaemias as second malignancies after preceding chemotherapy and/or
radiation.
transformation of preleukaemias.
Refractory Non-Hodgkin's lymphomas.

CONTRAINDICATIONS:

LARACIT is contraindicated in:

Patients with hypersensitivity to cytarabine.

Patients with drug-induced bone marrow suppression.

WARNINGS AND SPECIAL PRECAUTIONS:

LARACIT should be administered only under the supervision of medical specialists in oncology and the use of antineoplastic chemotherapeutic agents.

For induction therapy, patients should be treated in a facility with laboratory and supportive resources sufficient to monitor medicine tolerance and protect and maintain a patient compromised by medicine toxicity.

Anaphylaxis that resulted in acute cardiopulmonary arrest and required resuscitation, has been reported.

The main toxic effect of **LARACIT** is bone marrow suppression, possibly fatal, manifesting as leucopenia, particularly infection resulting from granulocytopenia, other impaired body defences, haemorrhage secondary to thrombocytopenia and anaemia, sometimes with striking megaloblastic changes. Myelosuppression is more evident after high doses and continuous infusions. Patients receiving this medicine must be under close medical

supervision and during induction therapy, should have leucocyte and platelet counts performed daily. Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood. Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count below 50 000 or a polymorphonuclear granulocyte count below 1 000/mm³. Counts of formed elements in the peripheral blood may continue to fall after the medicine is stopped and reach lowest values after medicine-free intervals of 12 to 24 days. When indicated, restart therapy when definite signs of marrow recovery appear (on successive bone marrow studies). Patients whose medicine is withheld until "normal" peripheral blood values are attained may escape from control.

Seizures and other manifestations of neurotoxicity may occur after intrathecal administration.

The human liver apparently detoxifies a substantial fraction of an administration dose. Use the medicine with caution and at reduced dose in patients whose liver function is poor. Regular checks of liver and kidney functions should also be performed in patients receiving **LARACIT**.

LARACIT may induce hyperuricaemia secondary to rapid lysis of neoplastic cells. The clinician should monitor the patient's blood uric acid level and be prepared to use such supportive and pharmacologic measures as might be necessary to control this problem.

Focal leukaemic involvement of the central nervous system may not respond to intrathecal **LARACIT** and may better be treated with radiotherapy. **LARACIT** given intrathecally may cause systemic toxicity and careful monitoring of the haemopoietic system is indicated. Modification of the anti-leukaemia therapy may be necessary.

PREGNANCY AND LACTATION:

Contraindicated as Cytarabine is teratogenic in animals.

DOSAGE AND DIRECTIONS FOR USE:

In cytostatic therapy:

If not otherwise defined in specific combinations: 3 - 6 mg/kg/day or 100 - 200 mg/m²/day.

For induction, **LARACIT** is administered as a rapid intravenous injection, short infusion or 8 – 24 hours continuous infusion. The duration of therapy is dependent on the haematological tolerance (bone marrow) and the clinical findings. With intravenous injection or short infusion, the daily dosage should be uniformly divided into several, at least two, administrations given at appropriate levels. See **WARNINGS AND SPECIAL PRECAUTIONS**. For maintenance of remission, **LARACIT** may also be administered intra muscularly or sub-cutaneously. Intracutaneous injection must be avoided. **LARACIT** can also be administered directly intrathecally. The solution for infusion may be prepared with a suitable diluent, such as physiological saline solution, 5 % glucose solution or sodium chloride-lactate for intrathecal use.

SIDE EFFECTS:

Adverse reactions reported as more than an isolated case is listed below, by system organ class and by frequency.

Frequencies are defined as: very common (> 1/10), common (>1/100, ≤ 1/10), uncommon (> 1/1000, ≤ 1/100), rare (≤ 1/1000).

Infections and infestations:

Uncommon: Sepsis, pneumonia

Blood and lymphatic system disorders:

Common: Anaemia, leucopenia, thrombocytopenia, megaloblastosis and reduced reticulocytes

Nervous system disorders:

Uncommon: Headache, dizziness, neural toxicity, neuritis, peripheral sensitivity

Rare: Severe and fatal central nervous system toxicity following high dose dosage schedules. These reactions include cerebral and cerebellar dysfunction.

Eye disorders:

Uncommon: Conjunctivitis may occur with rash.

Rare: Corneal toxicity.

Vascular disorders:

Common: Bleeding (all sites)

Respiratory, thoracic and mediastinal disorders

Uncommon: Shortness of breath, chest pain

Rare: Severe and fatal pulmonary toxicity following high dose dosage schedules. These reactions include pulmonary oedema. Reactions after intrathecal administration are nausea, vomiting and fever. Paraplegia has been reported as well as necrotizing leuco-encephalopathy.

Neurotoxicity has been reported and blindness occurred in patients in remission whose treatment had consisted of combination systemic chemotherapy, prophylactic central

nervous system radiation and intrathecal **LARACIT**.

Gastrointestinal disorders:

Common: Nausea, vomiting, diarrhoea, anorexia

Uncommon: Abdominal pain, oesophageal ulceration, oesophagitis

Rare: Severe and fatal gastrointestinal toxicity following high dose dosage schedules.

These reactions include severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis leading to peritonitis, sepsis and liver abscess.

Hepato-biliary disorders:

Common: Hepatic dysfunction

Uncommon: Jaundice

Skin and subcutaneous tissue disorders:

Common: Oral and anal inflammation or ulceration, rash.

Uncommon: Skin ulceration, pruritus, urticaria, alopecia, freckling.

Renal and urinary disorders:

Uncommon: Urinary retention, renal dysfunction

General disorders and administration site conditions:

Common: Thrombophlebitis, fever.

Uncommon: Cellulitis at injection site, sore throat, allergic oedema, anaphylaxis

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

There is no antidote for **LARACIT** overdosage. Refer to "Side Effects". Delayed or long-term adverse effects may result from the action on rapidly dividing normal cells in the bone marrow, lymphoreticular tissue, gastrointestinal mucosa, skin, gonad, and foetus.

Treatment: Control of nausea and vomiting may be attempted by giving phenothiazines such as perphenazine, prochlorperazine, promethazine, or thiethylperazine, before antineoplastic agents are administered. In bone marrow depression, transfusions of blood or platelets are given to diminish the risk of life-threatening haemorrhage. Granulocyte transfusions and injections of antibiotics may be necessary to combat infection in the neutropenic patient. Hyperuricaemia is avoided by the addition of allopurinol to treatment schedules and measures such as alkalinisation of the urine and hydration may also be adopted.

IDENTIFICATION:

Clear colourless solution, free from visible particles

PRESENTATION:

LARACIT 100 mg: Clear 5 ml glass vials, containing a 2 ml solution, with a bromobutyl rubber stopper and blue flip-off aluminium seal, in an outer container.

LARACIT 500 mg: Clear 14 ml glass vials, containing a 10 ml solution, with a bromobutyl rubber stopper and blue flip-off aluminium seal, in an outer container.

STORAGE INSTRUCTIONS:

Store at or below 25 °C, protected from light.

Keep out of reach of children.

REGISTRATION NUMBER:

LARACIT 100 mg: 37/26/0487

LARACIT 500 mg: 37/26/0488

NAME AND BUSINESS ADDRESS AND PARTICULARS OF ITS TREATMENT:

Teva Pharmaceuticals (Pty) Ltd

Suite 1, Building 4

Ruimsig Office Park

Hole in One Road

Ruimsig, Roodepoort

DATE OF PUBLICATION OF THIS PACKAGE INSERT:

Date of publication: 8 October 2004

Date of Regulation 9 submission: 18 March 2016